Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH), IMV Inc. (IMV) and Obalon Therapeutics Inc (OBLN)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Theravance Biopharma (TBPH), IMV Inc. (IMV) and Obalon Therapeutics Inc (OBLN).

Theravance Biopharma (TBPH)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Theravance Biopharma today and set a price target of $55. The company’s shares opened today at $23.77.

Chen noted:

“. We think it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of several important catalysts this year. We would also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It is well positioned to receive over $1B in milestones and payments, but its market cap is only $1.3B. Therefore, we think the peak sales potential of TBPH’s organ selective Trelegy, are underappreciated. Our positive investment thesis supports our OW rating and 12 month PT of $55.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.7% and a 47.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.

Currently, the analyst consensus on Theravance Biopharma is a Moderate Buy with an average price target of $47.50.

See today’s analyst top recommended stocks >>

IMV Inc. (IMV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV Inc. today and set a price target of $11.50. The company’s shares opened today at $3.90, close to its 52-week low of $3.60.

Pantginis observed:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S.”

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.7% and a 28.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IMV Inc. with a $11.50 average price target.

Obalon Therapeutics Inc (OBLN)

Northland Securities analyst Suraj Kalia maintained a Hold rating on Obalon Therapeutics Inc today and set a price target of $1. The company’s shares opened today at $1.41.

According to TipRanks.com, Kalia is a 5-star analyst with an average return of 11.0% and a 58.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.

Currently, the analyst consensus on Obalon Therapeutics Inc is a Moderate Buy with an average price target of $2.44.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts